Form Breast Health Supplement to the Medication Inventory (WHI Extension Study)

Size: px
Start display at page:

Download "Form Breast Health Supplement to the Medication Inventory (WHI Extension Study)"

Transcription

1 154 - Breast Health Supplement to the Medication Inventory (WHI ID WHI Participant Common ID Col#1 F154DAYS Days since randomization or enrollment Col#2 Days since randomization or enrollment to receipt of form N Missing Min Max Mean Std Dev , F154VTYP Visit Type Col#3 3 Annual visit F154VY Visit Year Col#4 Visit year in which this form was collected. N Missing Min Max Mean Std Dev BCTAMOX Ever taken tamoxifen Col#5 Since your breast cancer diagnosis: Have you ever taken tamoxifen (Novadex)? 0 No 3, Yes 2, Don't know Missing BCTAMOXDUR How long taken tamoxifen Col#6 Since your breast cancer diagnosis: How long did you take or have you taken tamoxifen? 1 Less than 1 month months months years years or more years 1, Missing 3, BCRALOX Ever taken raloxifene Col#7 Since your breast cancer diagnosis: Have you ever taken raloxifene (Evista)? 0 No 5, Yes Don't know Missing Page 1 of 6

2 154 - Breast Health Supplement to the Medication Inventory (WHI BCRALOXDUR How long taken raloxifene Col#8 Since your breast cancer diagnosis: How long did you take or have you taken raloxifene? 1 Less than 1 month months months years years or more years Missing 5, BCTOREM Ever taken toremifene Col#9 Since your breast cancer diagnosis: Have you ever taken toremifene (Fareston)? 0 No 5, Yes Don't know Missing BCTOREMDUR How long taken toremifene Col#10 Since your breast cancer diagnosis: How long did you take or have you taken toremifene? 1 Less than 1 month months months years years or more years Missing 5, BCANAST Ever taken anastrozole Col#11 Since your breast cancer diagnosis: Have you ever taken anastrozole (Arimidex)? 0 No 4, Yes 1, Don't know Missing BCANASTDUR How long taken anastrozole Col#12 Since your breast cancer diagnosis: How long did you take or have you taken anastrozole? 1 Less than 1 month months months years years or more years Missing 4, Page 2 of 6

3 154 - Breast Health Supplement to the Medication Inventory (WHI BCEXEME Ever taken exemestane Col#13 Since your breast cancer diagnosis: Have you ever taken exemestane (Aromasin)? 0 No 5, Yes Don't know Missing BCEXEMEDUR How long taken exemestane Col#14 Since your breast cancer diagnosis: How long did you take or have you taken exemestane? 1 Less than 1 month months months years years or more years Missing 5, BCLETRO Ever taken letrozole Col#15 Since your breast cancer diagnosis: Have you ever taken letrozole (Femara)? 0 No 4, Yes Don't know Missing BCLETRODUR How long taken letrozole Col#16 Since your breast cancer diagnosis: How long did you take or have you taken letrozole? 1 Less than 1 month months months years years or more years Missing 4, BCSERM Ever taken other SERM or aromatase inhibitor Col#17 Since your breast cancer diagnosis: Have you ever taken any SERM or aromatase inhibitor that is not listed above or that you may not recall the name of? 0 No 5, Yes Don't know Missing BCSERMDUR How long taken this other SERM or aromatase inhibitor Col#18 Page 3 of 6

4 154 - Breast Health Supplement to the Medication Inventory (WHI Since your breast cancer diagnosis: How long did you take or have you taken this medication (other SERM or aromatase inhibitor)? 1 Less than 1 month months months years years or more years Missing 5, BCBNONE Barrier-did not experience any Col#19 exemestane, and letrozole)?: I did not experience any barriers to taking these medications. 0 No 2, Yes 3, BCBNOHEAR Barrier-never heard of these meds Col#20 exemestane, and letrozole)?: I have never heard of these medications. 0 No 4, Yes BCBNOINSUR Barrier-insurance would not cover these meds Col#21 exemestane, and letrozole)?: My health insurance would not cover these medications. 0 No 5, Yes BCBCOST Barrier-meds cost too much Col#22 exemestane, and letrozole)?: These medications or copayments cost too much. 0 No 4, Yes Page 4 of 6

5 154 - Breast Health Supplement to the Medication Inventory (WHI BCBGETTODR Barrier-problem getting to physician Col#23 exemestane, and letrozole)?: It is a problem for me to get to my facility/physician. 0 No 5, Yes BCBINCONV Barrier-taking these meds inconvenient Col#24 exemestane, and letrozole)?: Taking these medications would be inconvenient. 0 No 5, Yes BCBSIDEEFF Barrier-concerned about side effects Col#25 exemestane, and letrozole)?: I was concerned about possible side effects or complications from these medications. 0 No 4, Yes BCBWORK Barrier-concerned about missing work Col#26 exemestane, and letrozole)?: I was concerned about missing work due to taking these medications. 0 No 5, Yes BCBFAMILY Barrier-family discouraged me from taking Col#27 exemestane, and letrozole)?: My family discouraged me from taking these medications. 0 No 5, Yes Page 5 of 6

6 154 - Breast Health Supplement to the Medication Inventory (WHI BCBFRIEND Barrier-friends discouraged me from taking Col#28 exemestane, and letrozole)?: My friends discouraged me from taking these medications. 0 No 5, Yes BCBTOOMANY Barrier-taking too many meds Col#29 exemestane, and letrozole)?: I am taking too many medications. 0 No 5, Yes BCBDISLIKE Barrier-don't like taking meds Col#30 exemestane, and letrozole)?: I don't like taking medications. 0 No 4, Yes BCBNORECOM Barrier-physician didn't recommend these meds Col#31 exemestane, and letrozole)?: My physician did not recommend these medications for my particular type of breast disease. 0 No 3, Yes 1, BCBOTHER Barrier-other Col#32 exemestane, and letrozole)?: Other 0 No 4, Yes F154FINDYS Days since randomization or enrollment to form finish Col#33 N Missing Min Max Mean Std Dev 5, , Page 6 of 6

A Layperson's Guide to Endocrine (Hormone) Therapy

A Layperson's Guide to Endocrine (Hormone) Therapy A Layperson's Guide to Endocrine (Hormone) Therapy What we will cover What is the endocrine system Basic definition of endocrine therapy Classes of endocrine drugs How you can utilise endocrine therapy

More information

A breast lump or thickening that feels different from the surrounding tissue

A breast lump or thickening that feels different from the surrounding tissue Breast Cancer Breast cancer is caused by abnormal cells that form in the breast tissue. Breast cancer is the most common cancer affecting South African women 1 in 35 women in South Africa will be diagnosed

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Ibrance) Reference Number: CP.PHAR.125 Effective Date: 10.01.15 Last Review Date: 11.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this policy

More information

Clinical Policy: Lapatinib (Tykerb) Reference Number: CP.PHAR.79 Effective Date: Last Review Date: 11.17

Clinical Policy: Lapatinib (Tykerb) Reference Number: CP.PHAR.79 Effective Date: Last Review Date: 11.17 Clinical Policy: (Tykerb) Reference Number: CP.PHAR.79 Effective Date: 10.01.11 Last Review Date: 11.17 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important

More information

After skin cancer, breast cancer is the most common cancer diagnosed in women in the United States.

After skin cancer, breast cancer is the most common cancer diagnosed in women in the United States. Diseases and Conditions Breast cancer By Mayo Clinic Staff Breast cancer is cancer that forms in the cells of the breasts. After skin cancer, breast cancer is the most common cancer diagnosed in women

More information

Systemic Treatment of Breast Cancer. Hormone Therapy and Chemotherapy, Curative and Palliative

Systemic Treatment of Breast Cancer. Hormone Therapy and Chemotherapy, Curative and Palliative Systemic Treatment of Breast Cancer Hormone Therapy and Chemotherapy, Curative and Palliative Systemic Therapy Invasive breast cancers Two forms Curative Palliative Curative Systemic Therapy Adjuvant Therapy

More information

Prescribing of endocrine therapy after breast cancer diagnosis

Prescribing of endocrine therapy after breast cancer diagnosis Prescribing of endocrine therapy after breast cancer diagnosis Gabrielle Emanuel, Katherine E Henson, John Broggio, Jackie Charman, Kieran Horgan, David Dodwell, Sarah C Darby National Cancer Registration

More information

MOST Operations Manual page 1 MEDICATION INVENTORY

MOST Operations Manual page 1 MEDICATION INVENTORY MOST Operations Manual page 1 TABLE OF CONTENTS MEDICATION INVENTORY 1. Background and rationale... 2 2. Equipment and supplies... 2 3. Detailed measurement procedures... 2 3.1 Drug definition guidelines...

More information

Clinical Policy: Toremifene (Fareston) Reference Number: CP.PMN.126 Effective Date: Last Review Date: Line of Business: Medicaid

Clinical Policy: Toremifene (Fareston) Reference Number: CP.PMN.126 Effective Date: Last Review Date: Line of Business: Medicaid Clinical Policy: (Fareston) Reference Number: CP.PMN.126 Effective Date: 04.01.10 Last Review Date: 05.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Verzenio) Reference Number: CP.PHAR.355 Effective Date: 10.24.17 Last Review Date: 05.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this

More information

Acknowledgement of Privacy Statement, Authorization and Assignments of Benefits. Release of Medical Information, Appointments and Prescriptions

Acknowledgement of Privacy Statement, Authorization and Assignments of Benefits. Release of Medical Information, Appointments and Prescriptions Acknowledgement of Privacy Statement, Authorization and Assignments of Benefits Patients Name (Please print) Date of Birth Guarantor s Name (Please print) Date of Birth (If patient is a minor or dependent)

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Verzenio) Reference Number: CP.PHAR.355 Effective Date: 10.24.17 Last Review Date: 02.19 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this

More information

Breast. Presentation Outline

Breast. Presentation Outline Breast FCDS 2011 Educational Webcast Series September 29, 2011 Mayra Espino, BA, RHIT, CTR Updated for 2011 Requirements and CSv02.03.02 Presentation Outline Overview Anatomy of Breast Multiple Primary

More information

Breast. FCDS 2011 Educational Webcast Series September 29, 2011 Mayra Espino, BA, RHIT, CTR Updated for 2011 Requirements and CSv02.03.

Breast. FCDS 2011 Educational Webcast Series September 29, 2011 Mayra Espino, BA, RHIT, CTR Updated for 2011 Requirements and CSv02.03. Breast FCDS 2011 Educational Webcast Series September 29, 2011 Mayra Espino, BA, RHIT, CTR Updated for 2011 Requirements and CSv02.03.02 Presentation Outline Overview Anatomy of Breast Multiple Primary

More information

Arimidex and mushroom supplements bank of america line of credit payoff address rachael ray weight gain 2017

Arimidex and mushroom supplements bank of america line of credit payoff address  rachael ray weight gain 2017 Arimidex and mushroom supplements bank of america line of credit payoff address rachael ray weight gain 2017 Totally unfiltered web search babita she gat mom lag time Sitemap Arimidex supplement. drink

More information

Adjuvant Systemic Therapy in Early Stage Breast Cancer

Adjuvant Systemic Therapy in Early Stage Breast Cancer Adjuvant Systemic Therapy in Early Stage Breast Cancer Julie R. Gralow, M.D. Director, Breast Medical Oncology Jill Bennett Endowed Professor of Breast Cancer Professor, Global Health University of Washington

More information

Clinical Policy: Pertuzumab (Perjeta) Reference Number: CP.PHAR.227 Effective Date: Last Review Date: Line of Business: HIM, Medicaid

Clinical Policy: Pertuzumab (Perjeta) Reference Number: CP.PHAR.227 Effective Date: Last Review Date: Line of Business: HIM, Medicaid Clinical Policy: (Perjeta) Reference Number: CP.PHAR.227 Effective Date: 06.01.16 Last Review Date: 05.18 Line of Business: HIM, Medicaid Coding Implications Revision Log See Important Reminder at the

More information

OSTEOPOROSIS ASSESSMENT CENTER

OSTEOPOROSIS ASSESSMENT CENTER OSTEOPOROSIS ASSESSMENT CENTER BOARD CERTIFIED RHEUMATOLOGISTS HERBERT S.B. BARAF, MD FACP MACR DAVID G. BORENSTEIN, MD FACP FACR ASHLEY D. BEALL, MD FACR ROBERT L. ROSENBERG, MD FACR CCD ROBERT J. LLOYD,

More information

Form 35 - Personal Habits Update

Form 35 - Personal Habits Update File ame Sep 12, 25 Aug 29, 212 ID WHI Participant Common ID Col#1 F35DAYS F35 Days since randomization Col#2 4 3892 1,522.382 872.618 F35VTYP Visit Type Col#3 2 Semi-Annual visit 2. 3 Annual visit 173,399

More information

4.7 Studies of Quality Holy Cross Hospital Bone Health Early Stage I ER/PR Positive Breast Cancer Patients December 13, 2017

4.7 Studies of Quality Holy Cross Hospital Bone Health Early Stage I ER/PR Positive Breast Cancer Patients December 13, 2017 4.7 Studies of Quality Holy Cross Hospital 2017 Bone Health Early Stage I ER/PR Positive Breast Cancer Patients December 13, 2017 Bone Health in Stage I ER/PR Positive Breast Cancer Patients To review

More information

Standard Breast Cancer Therapy

Standard Breast Cancer Therapy Pt s Who Don t Follow Treatment Standard Breast Cancer Therapy Deborah Thames R.T. (R)(M)(QM) Advancements in Breast Cancer Advancements in Breast Cancer Chemotherapy Full potential was recognized in the

More information

REFERENCE NUMBER: NH.PST.05 EFFECTIVE DATE: 10/10

REFERENCE NUMBER: NH.PST.05 EFFECTIVE DATE: 10/10 PAGE: 1 of 5 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted

More information

Breast Cancer. Dr. Andres Wiernik 2017

Breast Cancer. Dr. Andres Wiernik 2017 Breast Cancer Dr. Andres Wiernik 2017 Agenda: The Facts! (Epidemiology/Risk Factors) Biological Classification/Phenotypes of Breast Cancer Treatment approach Local Systemic Agenda: The Facts! (Epidemiology/Risk

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Spring LM, Gupta A, Reynolds KL, et al. Neoadjuvant endocrine therapy for estrogen receptor positive breast cancer: a systematic review and meta-analysis. JAMA Oncol. Published

More information

Cancer Genetics Unit Patient Information

Cancer Genetics Unit Patient Information Chemoprevention for women at an increased risk of familial breast cancer Cancer Genetics Unit Patient Information What is chemoprevention? Chemoprevention describes drugs that are used to reduce the risk

More information

Gynecologic Care for Breast Cancer Survivors. Case

Gynecologic Care for Breast Cancer Survivors. Case Gynecologic Care for Breast Cancer Survivors Mindy Goldman, MD Clinical Professor Dept. of Ob/Gyn and Reproductive Sciences Director, Women s Cancer Care Program, UCSF Breast Care Center and Women s Health

More information

Medical Review. The following slides were medically reviewed by Dr. Nancy Dawson in June 2018.

Medical Review. The following slides were medically reviewed by Dr. Nancy Dawson in June 2018. Bone Health Medical Review The following slides were medically reviewed by Dr. Nancy Dawson in June 2018. Presentation Overview 1. What is bone health? 2. How can cancer and cancer treatments affect your

More information

SOUTH TEXAS FRACTURE PREVENTION CLINIC PRE-DEXA PATIENT QUESTIONNAIRE

SOUTH TEXAS FRACTURE PREVENTION CLINIC PRE-DEXA PATIENT QUESTIONNAIRE OFFICE USE ONLY SOUTH TEXAS FRACTURE PREVENTION CLINIC PRE-DEXA PATIENT QUESTIONNAIRE PLACE STICKER HERE Name: Date of Birth: Male Female Primary Care Physician Name: Phone Number: Referring Physician

More information

Thank you for calling the Osteoporosis Assessment Center to schedule your DEXA (bone mineral density study) appointment on.

Thank you for calling the Osteoporosis Assessment Center to schedule your DEXA (bone mineral density study) appointment on. Dear Patient: Thank you for calling the Osteoporosis Assessment Center to schedule your DEXA (bone mineral density study) appointment on. Enclosed you will find forms relating to our financial policy,

More information

Safe Handling of Oral Anti cancer Agents: Perspectives from Breast Cancer Patients at National Cancer Centre

Safe Handling of Oral Anti cancer Agents: Perspectives from Breast Cancer Patients at National Cancer Centre Safe Handling of Oral Anti cancer Agents: Perspectives from Breast Cancer Patients at National Cancer Centre ABSTRACT Sim M.H. 1, Leow Y.C. 2 and Chan A. 3 Department of Pharmacy, Faculty of Science, National

More information

OPINION 3 April 2013

OPINION 3 April 2013 The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 3 April 2013 AFINITOR 5 mg, tablet B/30 (CIP: 34009 396 281 1 0) AFINITOR 10 mg, tablet B/30 (CIP: 34009 396 282 8

More information

Breast Cancer Prevention Studies. Key Points. Breast cancer prevention studies are clinical trials (research studies conducted with

Breast Cancer Prevention Studies. Key Points. Breast cancer prevention studies are clinical trials (research studies conducted with CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Breast Cancer Prevention

More information

Hormonal therapies for the adjuvant treatment of early oestrogenreceptor-positive

Hormonal therapies for the adjuvant treatment of early oestrogenreceptor-positive Hormonal therapies for the adjuvant treatment of early oestrogenreceptor-positive breast cancer Issued: November 2006 guidance.nice.org.uk/ta112 NICE 2006 Contents 1 Guidance... 3 2 Clinical need and practice...

More information

Increased Risk of Breast Cancer: Screening and Prevention. Elizabeth Pritchard, MD 4/5/2017

Increased Risk of Breast Cancer: Screening and Prevention. Elizabeth Pritchard, MD 4/5/2017 Increased Risk of Breast Cancer: Screening and Prevention Elizabeth Pritchard, MD 4/5/2017 No disclosures Defining Risk Risk Factors Modifiable Lifestyle obesity physical activity alcohol consumption breast

More information

W3C Life Sciences: Clinical Observations Interoperability: EMR + Clinical Trials Use-case for EMR + Clinical Trials Interoperability

W3C Life Sciences: Clinical Observations Interoperability: EMR + Clinical Trials Use-case for EMR + Clinical Trials Interoperability W3C Life Sciences: Clinical Observations Interoperability: EMR + Clinical Trials Use-case for EMR + Clinical Trials Interoperability Background: The key issue is to investigate whether some of the data

More information

Form 2 - Eligibility Screening

Form 2 - Eligibility Screening ID WHI Common ID Col#1 F2DAYS F2 Days since randomization Col#2 N Missing Min Max Mean Std Dev 0-1753 1107-145.472 153.960 F2CONT Contact type Col#3 The method used to collect the data. 1 Phone 65,083

More information

I have nothing to disclose

I have nothing to disclose What s So Important about Specialized Gynecology Care after Breast Cancer? Mindy Goldman, MD Clinical Professor Dept. of Ob/Gyn and Reproductive Sciences Director, Women s Cancer Care Program, UCSF Breast

More information

Breast Cancer Prevention for the Population at Large

Breast Cancer Prevention for the Population at Large Breast Cancer Prevention for the Population at Large Jack Cuzick Centre for Cancer Prevention Wolfson Institute of Preventive Medicine St Bartholomew s Medical School Queen Mary University of London London,

More information

Mdi Medical Management of Breast Cancer Morbidity and Mortality Aug 13, 2009 Irina Kovatch, PGY3 Introduction Metastatic disease is the principal cause of death from breast cancer Metastatic events often

More information

Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Quebec, Canada 3

Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Quebec, Canada 3 he Cardiovascular Safety of Aromatase Inhibitors and amoxifen in Post-Menopausal Women with Breast Cancer: A Systematic eview and Meta-Analysis of andomized Controlled rials Farzin Khosrow-Khavar MSc 1,2,

More information

Lecture 10: Hormonal agents

Lecture 10: Hormonal agents Lecture 10: Hormonal agents The survival and proliferation (growth) of some cancer cells is dependent on the action of steroid hormones. Early stage breast cancer and early stage prostate cancer are the

More information

Update from the 29th Annual San Antonio Breast Cancer Symposium

Update from the 29th Annual San Antonio Breast Cancer Symposium Update from the 29th Annual San Antonio Breast Cancer Symposium The San Antonio Breast Cancer Symposium is one of the most important breast cancer conferences. Approximately 8,000 physicians, oncologists,

More information

Use of Endocrine Therapy Data Points # 14

Use of Endocrine Therapy Data Points # 14 Use of endocrine therapy following diagnosis of ductal carcinoma in situ or early invasive breast cancer Use of Endocrine Therapy Data Points # 14 In 212, approximately 23, women in the United States were

More information

Beyond the Break. After Breast Cancer: Osteoporosis in Survivorship. Dr Alexandra Ginty CCFP(EM) FCFP Regional Primary Care Lead CCO

Beyond the Break. After Breast Cancer: Osteoporosis in Survivorship. Dr Alexandra Ginty CCFP(EM) FCFP Regional Primary Care Lead CCO Beyond the Break After Breast Cancer: Osteoporosis in Survivorship Dr Alexandra Ginty CCFP(EM) FCFP Regional Primary Care Lead CCO Disclosures No disclosures Osteoporosis in Breast Cancer Survivorship

More information

Treatment Options for Breast Cancer in Low- and Middle-Income Countries: Adjuvant and Metastatic Systemic Therapy

Treatment Options for Breast Cancer in Low- and Middle-Income Countries: Adjuvant and Metastatic Systemic Therapy Women s Empowerment Cancer Advocacy Network (WE CAN) Conference Bucharest, Romania October 2015 Treatment Options for Breast Cancer in Low- and Middle-Income Countries: Adjuvant and Metastatic Systemic

More information

Being cancer-free does not mean being free of cancer 2/26/17. What s Next? Survivorship Care Following Cancer Treatment. What is Survivorship?

Being cancer-free does not mean being free of cancer 2/26/17. What s Next? Survivorship Care Following Cancer Treatment. What is Survivorship? What s Next? Survivorship Care Following Cancer Treatment Kelli Cole-Vadjic, MS, PA-C Puget Sound Oncology Nursing Society 39 th Annual Oncology Nursing Symposium March 3, 2017 What is Survivorship? Survivor

More information

I have nothing to disclose. Mindy Goldman, MD. Case. Breast Cancer: What the Gynecologist Needs to Know

I have nothing to disclose. Mindy Goldman, MD. Case. Breast Cancer: What the Gynecologist Needs to Know Breast Cancer: What the Gynecologist Needs to Know Mindy Goldman, MD Clinical Professor Dept. of Ob/Gyn and Reproductive Sciences Director, Women s Cancer Care Program, UCSF Breast Care Center and Women

More information

The Latest Research: Hormonal Therapies

The Latest Research: Hormonal Therapies The Latest Research: Hormonal Therapies Sameer Gupta, M.D., M.P.H 9/29/2018 Attending Physician, Hematology/Oncology Bryn Mawr Hospital Clinical Assistant Professor, Jefferson Medical College Disclosures

More information

The Pharmacist s Role in Breast Cancer Awareness and Treatment

The Pharmacist s Role in Breast Cancer Awareness and Treatment The Pharmacist s Role in Breast Cancer Awareness and Treatment James A. Trovato, Pharm.D., BCOP Associate Professor University of Maryland School of Pharmacy This program has been supported by an educational

More information

Endocrine Therapy of Metastatic Breast Cancer

Endocrine Therapy of Metastatic Breast Cancer Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Endocrine Therapy of Metastatic Breast Cancer Endocrine Therapy of Metastatic Breast Cancer Version 2002: Gerber / Friedrichs

More information

Integrated care: guidance on fracture prevention in cancer-associated bone disease; treatment options

Integrated care: guidance on fracture prevention in cancer-associated bone disease; treatment options Paris, November 1st 2016 Integrated care: guidance on fracture prevention in cancer-associated bone disease; treatment options René Rizzoli MD International Osteoporosis Foundation and Division of Bone

More information

Section 5 Treatment and health service provision

Section 5 Treatment and health service provision Treatment and health service provision : Experience of treatment Treatments experienced The most common treatments were surgery (n=94, 94.00%) and Radiation therapy (n=79, 79.00%). This was followed by

More information

Hypertension and diabetes treatments and risk of adverse outcomes among breast cancer patients. Lu Chen

Hypertension and diabetes treatments and risk of adverse outcomes among breast cancer patients. Lu Chen Hypertension and diabetes treatments and risk of adverse outcomes among breast cancer patients Lu Chen A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy

More information

So, Who are the appropriate individuals that should consider genetic counseling and genetic testing?

So, Who are the appropriate individuals that should consider genetic counseling and genetic testing? Hello, I m Banu Arun, Professor of Breast Medical Oncology and Co-Director of Clinical Cancer Genetics at the University of Texas MD Anderson Cancer Center. Today I will be discussing with you Hereditary

More information

Setting The setting was secondary care. The economic study was carried out in Canada.

Setting The setting was secondary care. The economic study was carried out in Canada. Anastrozole is cost-effective vs tamoxifen as initial adjuvant therapy in early breast cancer: Canadian perspectives on the ATAC completed-treatment analysis Rocchi A, Verma S Record Status This is a critical

More information

Setting The study setting was secondary care. The economic study was carried out in Norway.

Setting The study setting was secondary care. The economic study was carried out in Norway. Comparing cost/utility of giving an aromatase inhibitor as monotherapy for 5 years versus sequential administration following 2-3 or 5 years of tamoxifen as adjuvant treatment for postmenopausal breast

More information

Bad to the bones: treatments for breast and prostate cancer

Bad to the bones: treatments for breast and prostate cancer 12 th Annual Osteoporosis: New Insights in Research, Diagnosis, and Clinical Care 23 rd July 2015 Bad to the bones: treatments for breast and prostate cancer Richard Eastell, MD FRCP (Lond, Edin, Ireland)

More information

Extended Hormonal Therapy

Extended Hormonal Therapy Extended Hormonal Therapy Dr. Caroline Lohrisch, Medical Oncologist, BC Cancer Agency Vancouver Centre November 1, 2014 www.fpon.ca Optimal Endocrine Therapy for Women with Hormone Receptor Positive Early

More information

American Society of Clinical Oncology June , New Orleans

American Society of Clinical Oncology June , New Orleans American Society of Clinical Oncology June 5-8 2004, New Orleans The 2004 annual meeting of the American Society of Clinical Oncology (ASCO) was held June 5 8 in New Orleans, Louisiana. This conference

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Proposed Health Technology Appraisal

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Proposed Health Technology Appraisal NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Proposed Health Technology Appraisal Everolimus in combination with exemestane for the treatment of advanced or metastatic HER2 negative, oestrogen

More information

Breast Cancer Treatments Breast surgery either breast conserving lumpectomy or modified mastectomy. May also include immediate or delayed reconstructi

Breast Cancer Treatments Breast surgery either breast conserving lumpectomy or modified mastectomy. May also include immediate or delayed reconstructi The Gynecologic Implications of Breast Cancer Mindy Goldman, MD Clinical Professor Dept. of OB/Gyn and Reproductive Sciences Director, Women s Cancer Care Program, Carol Franc Buck Breast Care Center and

More information

Manejo do câncer de mama RH+ na adjuvância: o que há de novo?

Manejo do câncer de mama RH+ na adjuvância: o que há de novo? II Simpósio Internacional de Câncer de Mama para o Oncologista Clínico Manejo do câncer de mama RH+ na adjuvância: o que há de novo? INGRID A. MAYER, MD, MSCI Assistant Professor of Medicine Director,

More information

Northumbria Healthcare NHS Foundation Trust. Your Guide to Endocrine Therapy. Issued by the Breast Team

Northumbria Healthcare NHS Foundation Trust. Your Guide to Endocrine Therapy. Issued by the Breast Team Northumbria Healthcare NHS Foundation Trust Your Guide to Endocrine Therapy Issued by the Breast Team This leaflet is to explain about your endocrine therapy. Your guide to endocrine therapy There are

More information

BREAST CANCER RISK REDUCTION

BREAST CANCER RISK REDUCTION BREAST CANCER RISK REDUCTION Clinical Practice Guideline Update Introduction ASCO published its first breast cancer risk reduction (BCRR) guideline in 1999 ASCO Guidelines are updated at intervals by an

More information

Extension Study 2, Self Reported, Non-Adjudicated Outcomes for MRC Participants

Extension Study 2, Self Reported, Non-Adjudicated Outcomes for MRC Participants Extension Study 2, Self Reported, on-adjudicated Outcomes for s File ame A self report is only counted if the first report of that outcome occurred after the start of the extension 2 phase of the study.

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Overview

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Overview NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Overview Hormonal therapies for the adjuvant treatment of early oestrogen-receptor positive breast cancer The overview is written by members of the

More information

Surviving Breast Cancer

Surviving Breast Cancer Surviving Breast Cancer What to expect after completing treatment Dexter T. Estrada, MD Hematology Oncology Medical Group of Fresno, Inc. November 3, 2012 Epidemiology & Survival Estimates Breast cancer

More information

Hormonal Therapies for Breast Cancer. Westmead Breast Cancer Institute

Hormonal Therapies for Breast Cancer. Westmead Breast Cancer Institute Hormonal Therapies for Breast Cancer Westmead Breast Cancer Institute Hormonal (endocrine) therapies for breast cancer (also called anti-hormone treatment ) Hormonal therapy is used to treat breast cancers

More information

Form 45 - Current Supplements

Form 45 - Current Supplements File ame Sep 12, 25 Aug 29, 212 ID WHI Participant Common ID Col#1 F45DAYS F45 Days since randomization/enrollment Col#2-595 3892 81.77 887.279 F45VTYP Visit Type Col#3 Value Description % 1 Screening

More information

Breast cancer has the highest incidence among those

Breast cancer has the highest incidence among those Medical Treatment of Breast Cancer Young Seon Hong, M.D. Department of Internal Medicine Catholic University of Korea, St. Mary's Hospital E mail : y331@cmc.cuk.ac.kr Abstract Breast cancer has the highest

More information

The Role of Aromatase Inhibitor (AI) in The Treatment of Breast Cancer

The Role of Aromatase Inhibitor (AI) in The Treatment of Breast Cancer R E V I E W A R T I C L E The Role of Inhibitor (AI) in The Treatment of Breast Cancer Cosphiadi Irawan, Abdulmuthalib INTRODUCTION Discussion on the topic with the same title above would never be separated

More information

Healthcare Cost-Effectiveness Analysis for Older Patients: Using Cataract Surgery and Breast Cancer Treatment Data. Chapter 5

Healthcare Cost-Effectiveness Analysis for Older Patients: Using Cataract Surgery and Breast Cancer Treatment Data. Chapter 5 Healthcare Cost-Effectiveness Analysis for Older Patients: Using Cataract Surgery and Breast Cancer Treatment Data Chapter 5 Decision Analysis Modeling of the Adjuvant Treatment of Older Patients with

More information

Breast Cancer CANCERCARE CONNECT BOOKLET SERIES

Breast Cancer CANCERCARE CONNECT BOOKLET SERIES CANCERCARE CONNECT BOOKLET SERIES Treatment Update Breast Cancer With Advances in the Treatment of HER2-Positive Breast Cancer and Highlights From the 2012 San Antonio Breast Cancer Symposium www.cancercare.org

More information

/ NCCN. ACS (www.cancer.org) NCC (www.nccn.org) NCCN NCCN ACS ACS-2345

/ NCCN. ACS (www.cancer.org) NCC (www.nccn.org) NCCN NCCN ACS ACS-2345 /2002 9 /2002 9 (NCCN) (ACS) NCCN ACS (www.cancer.org) NCC (www.nccn.org) NCCN 1-888-909-NCCN ACS 1-800-ACS-2345 NCCN ACS NCCN NCCN ACS NCCN 2002 (NCCN) (ACS) NCCN ACS ...................................

More information

Thioredoxin and Jab1 Control Estrogen- and Antiestrogen-Mediated Progression of the Cell Cycle Through p27 Interactions

Thioredoxin and Jab1 Control Estrogen- and Antiestrogen-Mediated Progression of the Cell Cycle Through p27 Interactions Florida International University FIU Digital Commons FIU Electronic Theses and Dissertations University Graduate School 3-11-2011 Thioredoxin and Jab1 Control Estrogen- and Antiestrogen-Mediated Progression

More information

Figure 1: PALLAS Study Schema. Endocrine adjuvant therapy may have started before randomization and be ongoing at that time.

Figure 1: PALLAS Study Schema. Endocrine adjuvant therapy may have started before randomization and be ongoing at that time. Figure 1: PALLAS Study Schema Endocrine adjuvant therapy may have started before randomization and be ongoing at that time. Approximately 4600 patients from approximately 500 global sites will be randomized

More information

Evaluation & Management of PowerPoint Cover Title. the High Risk Population. High Risk Clinic

Evaluation & Management of PowerPoint Cover Title. the High Risk Population. High Risk Clinic Evaluation & Management of PowerPoint Cover Title the High Risk Population High Risk Clinic Subtitle Joanna Would Springman, Go Here PA-C Assessment Genetics Known genetic mutation Family history with

More information

Anti-aromatase Agents in the Treatment and Prevention of Breast Cancer

Anti-aromatase Agents in the Treatment and Prevention of Breast Cancer Based on their activity in the metastatic setting, anti-aromatase agents are now being evaluated in the adjuvant setting and in pilot studies for chemoprevention. Michele Sassi. La Digue Island, c. 2001.

More information

Index. Note: Page numbers of article titles are in boldface type.

Index. Note: Page numbers of article titles are in boldface type. Note: Page numbers of article titles are in boldface type. A Adjuvant therapy, for early-stage triple-negative breast cancer, 740 742 in older early-stage breast cancer patients, 790 795 anti-her2-directed

More information

Population: All participants Number of Obs: Variable # Sas Name: Sas Label: Categories: Variable # Sas Name: F43VNUM. Sas Label: Categories:

Population: All participants Number of Obs: Variable # Sas Name: Sas Label: Categories: Variable # Sas Name: F43VNUM. Sas Label: Categories: Data File: form4dat Last Update: 04/6/00 umber of Obs: 6809 Participant ID ID Participant ID Study: Administration F4 Days since randomization/enrollment 04-595 7-504 59476 F4DAYS F4 Days since randomization/enrollment

More information

BREAST CANCER AND BONE HEALTH

BREAST CANCER AND BONE HEALTH BREAST CANCER AND BONE HEALTH Rowena Ridout, MD, FRCPC Toronto Western Hospital Osteoporosis Program University Health Network / Mount Sinai Hospital rowena.ridout@uhn.ca None to declare Conflicts of Interest

More information

Breast cancer remains the most common malignancy and the second leading. cause of cancer mortality in women in the United States.

Breast cancer remains the most common malignancy and the second leading. cause of cancer mortality in women in the United States. Dr. Andrew Seidman s Commentary I. Breast Cancer Overview Breast cancer remains the most common malignancy and the second leading cause of cancer mortality in women in the United States. The following

More information

Women s Health: Breast Cancer Screening. K. Rast, MD and E. McNany, MD

Women s Health: Breast Cancer Screening. K. Rast, MD and E. McNany, MD Women s Health: Breast Cancer Screening K. Rast, MD and E. McNany, MD 2013 2017 Update: Who? How? When? Cases and Practice Questions Question 1 A 40 year old female comes to your office for a well woman

More information

Emerging Approaches for (Neo)Adjuvant Therapy for ER+ Breast Cancer

Emerging Approaches for (Neo)Adjuvant Therapy for ER+ Breast Cancer Emerging Approaches for (Neo)Adjuvant Therapy for E+ Breast Cancer Cynthia X. Ma, M.D., Ph.D. Associate Professor of Medicine Washington University in St. Louis Outline Current status of adjuvant endocrine

More information

ART Drugs. Description

ART Drugs. Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.08.02 Subject: ART Drugs Page: 1 of 7 Last Review Date: December 3, 2015 ART Drugs Description Bravelle

More information

Form 2023 R2.0: Ovarian Cancer Pre-HSCT Data

Form 2023 R2.0: Ovarian Cancer Pre-HSCT Data Key Fields Sequence Number Date Received: - - CIBMTR Center Number: CIBMTR Recipient ID: Today's Date: - - Date of HSCT for which this form is being completed: - - HSCT type: (check all that apply) Autologous

More information

Access To Cancer Drugs In Medicare Part D: Formulary Placement And Beneficiary Cost Sharing In 2006

Access To Cancer Drugs In Medicare Part D: Formulary Placement And Beneficiary Cost Sharing In 2006 Access To Cancer Drugs In Medicare Part D: Formulary Placement And eneficiary Cost Sharing In 2006 Medicare Part D beneficiaries have access to many more cancer drugs than ever before, with low cost sharing.

More information

Metastatic breast cancer: sequence of therapies

Metastatic breast cancer: sequence of therapies Metastatic breast cancer: sequence of therapies Clinical Case Discussion Nadia Harbeck, MD PhD Breast Center, Department of Gynecology and Obstetrics University of Munich, Ludwig-Maximilians University

More information

POSITION PAPER FOR HEALTH CARE PROVIDERS Use of Pharmacologic Intervention for Breast Cancer Risk Reduction

POSITION PAPER FOR HEALTH CARE PROVIDERS Use of Pharmacologic Intervention for Breast Cancer Risk Reduction P.O. Box 30195 Lansing, MI 48909 Phone: 877-588-6224 FAX: 517-335-9397 www.michigancancer.org Introduction POSITION PAPER FOR HEALTH CARE PROVIDERS Use of Pharmacologic Intervention for Breast Cancer Risk

More information

Endocrine Therapy 2017: Is There a Better Single Agent and when Should we Use it?

Endocrine Therapy 2017: Is There a Better Single Agent and when Should we Use it? Endocrine Therapy 2017: Is There a Better Single Agent and when Should we Use it? ET1 ET2 ET3 Targeted agent 1 Targeted agent 2 Hope S. Rugo, MD Director, Breast Oncology and Clinical Trials Education

More information

Risk Assessment, Genetics, and Prevention

Risk Assessment, Genetics, and Prevention Risk Assessment, Genetics, and Prevention Katherine D. Crew, MD MS Director, Clinical Breast Cancer Prevention Program Columbia University Medical Center 1 Outline Breast cancer risk factors Hereditary

More information

Giuseppe Viale for the BIG 1 98 Collaborative and International Breast Cancer Study Groups

Giuseppe Viale for the BIG 1 98 Collaborative and International Breast Cancer Study Groups Central Review of ER, PgR and HER2 in BIG 1 98 Evaluating Letrozole vs. Letrozole Tamoxifen vs. Tamoxifen Letrozole as Adjuvant Endocrine Therapy for Postmenopausal Women with Hormone Receptor Positive

More information

A review of adjuvant hormonal therapy in

A review of adjuvant hormonal therapy in REVIEW Endocrine-Related Cancer (2004) 11 391 406 A review of adjuvant hormonal therapy in breast cancer Kellie L Jones and Aman U Buzdar 1 Department of Pharmacy, University of Texas M.D. Anderson Cancer

More information

The Estrogen Question

The Estrogen Question The Estrogen Question Hormone Therapy still offers the best relief for menopausal symptoms. Is it right for you? When 49-year-old Lee Ann Dodson heard the news that the Women's Health Initiative (WHI)

More information

ART Drugs. Description

ART Drugs. Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.02 Subject: ART Drugs Page: 1 of 7 Last Review Date: September 15, 2017 ART Drugs Description Bravelle

More information

OPTIMAL ENDOCRINE THERAPY IN EARLY BREAST CANCER

OPTIMAL ENDOCRINE THERAPY IN EARLY BREAST CANCER OPTIMAL ENDOCRINE THERAPY IN EARLY BREAST CANCER STEPHEN E. JONES, M.D. US ONCOLOGY RESEARCH THE WOODLANDS, TX TOPICS PREMENOPAUSAL BREAST CANCER POSTMENOPAUSAL BREAST CANCER THE FUTURE TOPICS PREMENOPAUSAL

More information